A detailed history of Bourgeon Capital Management LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Bourgeon Capital Management LLC holds 33,060 shares of ETNB stock, worth $262,496. This represents 0.05% of its overall portfolio holdings.

Number of Shares
33,060
Previous 33,650 1.75%
Holding current value
$262,496
Previous $269,000 9.29%
% of portfolio
0.05%
Previous 0.05%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$7.36 - $9.66 $4,342 - $5,699
-590 Reduced 1.75%
33,060 $244,000
Q1 2024

Apr 19, 2024

SELL
$8.13 - $13.77 $13,414 - $22,720
-1,650 Reduced 4.67%
33,650 $391,000
Q4 2023

Jan 30, 2024

SELL
$6.66 - $16.03 $134,532 - $323,806
-20,200 Reduced 36.4%
35,300 $394,000
Q3 2023

Nov 01, 2023

BUY
$15.06 - $19.41 $384,030 - $494,955
25,500 Added 85.0%
55,500 $856,000
Q2 2023

Jul 20, 2023

BUY
$14.15 - $22.03 $164,847 - $256,649
11,650 Added 63.49%
30,000 $568,000
Q1 2023

Apr 17, 2023

BUY
$10.48 - $16.94 $181,828 - $293,909
17,350 Added 1735.0%
18,350 $279,000
Q4 2022

Jan 20, 2023

SELL
$5.52 - $12.73 $8,280 - $19,095
-1,500 Reduced 60.0%
1,000 $0
Q3 2022

Oct 27, 2022

SELL
$3.02 - $7.0 $88,939 - $206,150
-29,450 Reduced 92.18%
2,500 $14,000
Q2 2022

Jul 27, 2022

BUY
$2.09 - $4.02 $2,090 - $4,019
1,000 Added 3.23%
31,950 $103,000
Q1 2022

May 03, 2022

BUY
$3.45 - $14.99 $36,570 - $158,894
10,600 Added 52.09%
30,950 $117,000
Q4 2021

Jan 31, 2022

SELL
$11.15 - $19.66 $18,955 - $33,422
-1,700 Reduced 7.71%
20,350 $266,000
Q2 2021

Jul 19, 2021

BUY
$17.42 - $28.0 $67,067 - $107,800
3,850 Added 21.15%
22,050 $412,000
Q1 2021

May 13, 2021

BUY
$20.22 - $26.73 $208,266 - $275,319
10,300 Added 130.38%
18,200 $431,000
Q4 2020

Jan 29, 2021

BUY
$23.16 - $28.08 $78,744 - $95,472
3,400 Added 75.56%
7,900 $193,000
Q3 2020

Oct 28, 2020

BUY
$24.34 - $38.82 $109,530 - $174,690
4,500 New
4,500 $115,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $369M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Bourgeon Capital Management LLC Portfolio

Follow Bourgeon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bourgeon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bourgeon Capital Management LLC with notifications on news.